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The pharmaceutical sector is constantly developing, but
we have seldom seen as many changes under way simul-
taneously as we will see during this summer season. The
Finnish reform of pharmaceutical legislation will lead to
the authorities having to revise extensively many de-
crees, rules and regulations. The much-discussed regula-
tions on the advertising  of medicinal products, the re-
strictions on the importation of medicines by private in-
dividuals, and many other issues, which have until now
been under the control of the National Agency for Med-
icines (NAM) only, should then be finalised. 
Our state constitution now calls for additional atten-
tion with regard to the activities of citizens and entre-
preneurs. Mandates for regulations and guidelines  must
be clear, rules and regulations must be set at the appro-
priate level, and the powers of authorities shall be clear-
ly enough defined. It is hoped that the reform process
will be a success now that the Ministry of Social Affairs
and Health will become the principal actor defining and
setting up the normative framework in the field of phar-
maceutical control. The role of the National Agency for
Medicines will be to focus on practical enforcement un-
der the regulatory framework. 
Another significant national project concerns the for-
mulation of our pharmaceutical policy, which is current-
ly in progress at the Ministry of Social Affairs and
Health. It is reasonable to presume that aspects of our
policy  will be subject to public debate this coming au-
tumn. The underlying principles of a policy, be it of
medicines or any of other field, should point the way to
future developments or trends. 
There are many goods reasons for formulating a
pharmaceutical policy on medicines. In NAM’s view,
they include ensuring drug safety and the availability of
medicines, Finland’s objectives and profile as a partici-
pant in the activities of the EU in the field of medicines
control, and in defining the basic  principles of retail
pharmacies and their operations. Knowing the preferred
directions and trends will make it easier for all actors in
pharmaceutical services to function. This is particularly
important when trends are partly set by actors external
to health policy. 
The winds of change are also blowing within the Eu-
ropean Union. The European Parliament and the Coun-
cil of the European Union are dealing with the motion
on a reform the legislation on pharmaceuticals, which
the European Commission put forward last year. In
health care services and for the citizens, the reforms
might manifest themselves as faster marketing authori-
sation procedures for new medicines, and an increasing
volume of information on prescription medicines be-
coming available to the consumer. Whether these re-
forms will be implemented, remains to be seen in the
course of the lengthy legislative process.
Some other developments of the pharmaceutical poli-
cy of the European Union are also pending. The G10
Medicines report was recently produced (http://pharma-
cos.eudra.org/). It comprises an initiative by a working
group under Commissioners Erkki Liikanen (Enterprise
and Information Society) and David Byrne (Health and
Consumer Protection) to find new ways to promote in-
novations and competitiveness of the pharmaceutical in-
dustry in the EU. The interests of public health and so-
cial security were also focused on. The proposals includ-
ed in the final report cover just about everything of sig-
nificance to the pharmaceutical industry: The industry’s
competitiveness, medicines control, the use of informa-
tion technology, price control and drug reimbursement
systems, generic medicinal products, OTC or self-care
products, the relative value and cost-effectiveness of
medicines, networking of research activity, creation of
incentives, improving the information available to pa-
tients, and taking into account the expansion of the EU.
Some of these items have already been dealt with by the
Commission in its proposal. 
Some of the proposals of the G10 report fall clearly
within the mandate of member states. Such proposals
include the application of drug reimbursement systems,
and the promotion of prescribing and dispensing of
generic medicines. It is interesting to note that these ma-
jor issues of pharmaceutical policy in the EU do not
seem to include the retail sale of medicines. In the
Finnish media, the public debate seems to rate the rela-
tive importance of the above issues quite differently. 
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The mechanisms of developing arte-
rial and venous thrombosis differ
from each other. Arterial thrombosis
is initiated by platelets becoming at-
tached to the damaged arterial wall,
while venous thrombosis is often
brought about by inborn or ac-
quired defects in the clotting-factor-
regulating systems. Problems arise
under situations where the patient is
liable to increased blood clotting,
such as in pregnancy or during im-
mobilisation. Malignant tumours,
and inflammatory cells which are
activated during infection secrete
proteases with clotting activity and
tissue factor which is a powerful ac-
tivator of the extrinsic pathway of
the clotting system. Inflammation is
associated with an increased risk of
thrombosis. Cancer has been re-
vealed as a factor underlying idio-
pathic thrombosis in about 15% of
cases, usually diagnosed within a
couple of months after the thrombo-
sis (1).
The specific clotting system dis-
orders causing arterial thrombosis
are, with the exception of phospho-
lipid antigen syndrome, far less sig-
nificant than those causing venous
thrombosis. The classic risk factors
of arterial thrombosis are disorders
of the lipid metabolism, hyperten-
sion, smoking, stress and diabetes or
insulin resistance, which promote
atherosclerosis of the arterial wall
and activate platelet function. Topi-
cal arterial wall inflammations as
well as more generalized inflamma-
tions increase the risk of arterial
thrombosis. Furthermore, it is often
unusually difficult to treat arterial
thrombosis in a patient whose arter-
ies are affected with atherosclerosis
and whose circulating blood is si-
multaneously prone to clot due to
thrombophilia (2). 
In thrombophilia, the blood clot-
ting reaction exceeds its capacity to
compensate. As many as 70% of pa-
tients with thromboembolism have
underlying thrombophilia (3). Its
most common hereditary causes are
mutations in the genome affecting
the clotting Factor V (FV Leiden)
and prothrombin. Direct deficiencies
in the quantity of clotting regulators
are rarer. Acquired phospholipid
antigen syndrome, either alone or in
association with infection, vasculitis,
cancer or drug effects, also explains
about a fifth of the occurrences of
venous thrombosis. Homocystinae-
mia, which increases the liability to
arterial and venous blood clotting, is
especially common in vitamin B6,
B12 or folic acid deficiency. This es-
pecially affects elderly patients who
smoke and are suffering from exten-
sive atherosclerosis. Administration
of vitamin supplements to patients
with a thrombotic predisposition is
important (4). It would be helpful if
the pathogenetic mechanisms were
to be determined prior to selecting
the medication for inhibition of the
thrombotic predisposition.
Antithrombotic treatment 
alternatives
Platelet inhibitors such as acetylsali-
cylic acid (ASA, 50–325 mg) and
clopidogrel (75 mg) are effective in
the prevention of recurrencies of ar-
terial thrombosis. Warfarin (INR
target 2.0–3.0) and low-molecular-
weight heparin are most effective in
the prophylaxis of venous thrombo-
sis. In patients with atrial fibrillation
and/or impaired left ventricular
function (EF below 35%), warfarin
(INR target 2.0–3.0) will be effective
because clots develop in a situation
of stasis. Clots embolised from the
aortic arch are also of a similar type
due to the circular flow forces tar-
geted at the wall, and warfarin will
be effective in these situations, too.
The same applies to embolisms
despatched by an artificial cardiac
valve, but they require stricter anti-
coagulation (INR target 2.5–3.5).
The treatment of patients with a
special predisposition to the risk of
thrombosis should also include ASA
(50–100 mg), since platelets are acti-
vated in the flow conditions of the
artificial cardiac valve. Combination
therapy nevertheless requires careful
monitoring of the patient (drug in-
teractions, INR, thrombocyte count
and anaemia), as the risk of haemor-
rhage is increased, particularly in el-
derly patients.
For primary prevention of
atherothrombosis, ASA is recom-
mended at a dose level of 50–100
mg in individuals especially at risk
(e.g. those with type 2 diabetes).
The platelet-inhibiting effect of ASA
may be limited in some patients, but
part of its effect is to curb the devel-
opment of inflammation. It is debat-
able whether a dose of 50–100 mg is
sufficient if a potent inflammatory
reaction is present in the vascular
wall. The co-administration of
ibuprofen or indomethacin is not
appropriate with aspirin because the
platelet inhibiting effect of aspirin
would be significantly reduced (5).
In a patient prone to haemorrhage,
cox-2-selective coxibs may be tried
as an analgesic because they do not
impair the platelet function.
Clopidogrel, a platelet ADP-acti-
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vation inhibitor, should be intro-
duced if the patient does not tolerate
ASA in general or the patient’s other
risk factors are under control and an
atherothrombotic event occurs de-
spite the administration of ASA. A
combination therapy of ASA and
clopidogrel for 3–4 weeks is used as
follow-up treatment after arterial
stenting to prevent (sub)acute
platelet-induced thrombosis. Three
months upto one year following un-
stable angina pectoris the combina-
tion therapy of ASA and clopidogrel
prevented about 20% of the throm-
botic events of coronary artery dis-
ease compared with a control group
of patients on ASA alone (6).
If thrombosis recurs despite an
appropriate INR level, the question
becomes one of an exceptional pre-
disposition to thrombosis, where the
cause is a combined congenital
and/or acquired defect. There is of-
ten an underlying phospholipid anti-
gen syndrome, in which case the
thrombosis would recur despite war-
farin being in the target region of
2.5–3.5 and ASA having been added
to the therapy. In this case warfarin
should be replaced by permanent
subcutaneous low-molecular-weight
heparin. Treatment-resistant predis-
position to thrombosis occurs in
cancer patients, and on-going stud-
ies will determine the effect of con-
tinuous low-molecular-weight he-
parin therapy on the mechanisms
promoting the progress of cancer as
well as on the liability to thrombo-
sis.
Considerable improvement is re-
quired in the prevention of liability
to thrombosis in association with
surgery. The fact still remains that
about 25–45% of patients with deep
vein thrombosis or pulmonary em-
bolism have actually undergone a
surgical operation during the pre-
ceding month (7). Thrombotic pro-
phylaxis is absolutely necessary in
orthopaedics, extensive cancer
surgery in the hip or abdominal
area, and even with laparoscopy.
The benefit of long-term prophylax-
is (4 weeks) has been especially
proven in arthroplasty of the hip
and the knee, and in cancer surgery
(8,9). The most recent addition to
the treatment of thrombotic prophy-
laxis is the selective clotting Factor
Xa inhibitor, fondaparinux, which
improves the AT3 function. The effi-
cacy of fondaparinux is twice that
of enoxaparin when their use for
thrombosis prophylaxis has been
compared (10).
New thrombin-inhibitors which
would replace warfarin in long-term
thrombotic prophylaxis are expected
to be introduced. On-going phase III
trials will evaluate the efficacy of
oral ximelagatran in thrombotic
prophylaxis and treatment, and in
the prevention of thromboembolic
complications associated with atrial
fibrillation. 
Studying procoagulant properties
of adhesive platelet receptors and
membranes could be helpful in the
future. It should be possible e.g. to
identify patients responding poorly
to aspirin and to optimise anti-
thrombotic treatment following arte-
rial thrombosis.
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The main individual health risk
among Finns is the use of intoxi-
cants, especially alcohol.  The over-
all consumption of alcohol in 2001
amounted to about 9.2 litres of ab-
solute alcohol per inhabitant and it
appears to be steadily on the in-
crease.  Nearly 90% of Finns drink
alcohol.  The mid-European wine-
drinking culture does not seem to
have become a substitute for our al-
cohol-drinking habit, the actual aim
of which is purely intoxication, but
appears instead, simply to supple-
ment the customary habitual drink-
ing.  Besides the direct effects that
alcohol has on our health, alcohol
consumption on this scale will also
increase the indirect harmful effects
including the problems arising from
various concurrent medications and
other interactions.
Heavy users of alcohol
A person drinking in excess of four
restaurant doses of alcohol per day
can be considered a heavy user.  The
number of heavy users in Finland is
probably 300,000, and the majority
are in active working life.  Absen-
teeism from work due to ill health
among heavy users is double com-
pared with that among normal con-
sumers, and the number of appoint-
ments they make with their doctors
and days of hospitalisation are sev-
en-fold in comparison.  Heavy users
also have a seven-fold mortality risk
compared with the normal popula-
tion.  About 2,500 people annually
die in Finland as a result of alcohol
consumption.  Alcohol poisoning is
the most common cause of death by
poisoning in Finland with an ap-
proximate annual death toll of 500
people.  Alcohol is the cause of a
significant number of accidents and
violent crimes.
Alcohol-induced diseases
The most common alcohol-induced
diseases affect the nervous system
(dementia, Wernicke-Korsakoff’s
syndrome, cerebellar degeneration,
polyneuropathy) and alimentary
tract (gastritis, hepatitis, cirrhosis of
the liver, pancreatitis).  Alcohol also
affects the haemopoietic tissue, im-
mune system and hormonal balance.
In 2000, about 26,000 people suf-
fered from an alcohol-induced dis-
ease which required hospitalisation.
Medical treatment of alcohol 
dependence
Alcoholism is a chronic recurring
state with an underlying develop-
ment of tolerance and obsessive
need to have alcohol.  We no longer
speak of physical and mental depen-
dence, but of pleasure-seeking be-
haviour which is controlled by the
mesolimbic-hypothalamic dopamine-
induced reward-and-pleasure system
of the brain, the most important
anatomical constituent of which is
the nucleus accumbens.  The plea-
surable sensation will undergo con-
siderable neurochemical change in
this centre, and by influencing it, we
can also influence alcohol consump-
tion.
The development of treatment
methods in alcoholism in recent
years has been rapid.  The treatment
is based on various models of func-
tional and cognitive-behavioural
therapy, treatment of co-existent dis-
eases and withdrawal symptoms,
and the medical treatment of depen-
dence.  Inadequacy of medical proof
based on evidence of the efficacy of
the various therapies is a problem.
Controlled Antabus therapy has
proven to be effective in some alco-
holics.  Drugs available in many Eu-
ropean countries specifically aimed
at alcohol dependence include nal-
trexone, nalmefene and acampros-
ate. The anti-emetic, ondansetron
(selective 5-HT3 antagonist), has
been used in the treatment of alco-
holism.
Naltrexone is an opiate antago-
nist which has proven effective not
only in the withdrawal treatment of
narcotics abuse but also in the treat-
ment of alcoholism.  The medical
costs of naltrexone in the treatment
of alcohol dependence in Finland are
only reimbursed if the drug is used
as part of other treatment, at ap-
proved doses and in approved cir-
cumstances.  Naltrexone used in
conjunction with a re-educational
therapy will reduce the frequency of
relapses in patients who are motivat-
ed towards their treatment.  After
regular treatment over a couple of
months, naltrexone taken as re-
quired will also abate the urge for
alcohol relatively well.  Naltrexone
therapy has not been associated with
especially complicated adverse ef-
fects.
Medical treatment of actual alco-
holism is at present limited.  Consid-
ering the rapid development of neu-
robiology  it is likely that highly se-
lective drugs aimed at the treatment
of dependence will become available
within a few years.
What's wrong with the Finnish alcohol policy?
Juhani Juntunen
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Incapacity for work caused by 
alcohol consumption
The harmful health effects of alco-
hol are also reflected in the number
of people retiring each year on dis-
ability pensions due to alcohol-in-
duced diseases.  An individual can
be considered incapacitated for
work due to alcohol consumption if
he or she suffers from alcohol-in-
duced organic or mental diseases
due to which the ability to function
is permanently reduced, or if the al-
cohol dependence is otherwise so se-
vere that it is unreasonable to expect
the individual to return to work.
An individual who would be able to
work if he or she did not drink alco-
hol cannot be considered entitled to
a disability pension.  Statistics of
1994–1999 show that the number of
entitlements to disability pensions
due to alcohol abuse has increased
steadily, amounting to about 3.5%
of all disability pensions at present.
The true share of the number of dis-
ability pensions where alcohol is the
cause is nevertheless higher than is
shown in the statistics, since alco-
hol-induced diseases are often
masked by other diseases and alco-
hol consumption is often concealed.
Alcohol and the career
The connection between the individ-
ual’s alcohol consumption and ca-
reer is interesting.  The LEL (Tem-
porary Employees) Employment
Pension Fund in Finland offers em-
ployment pension security in the
building, forestry, agriculture and
harbour sectors.  11% of all entitle-
ments to disability pensions within
the LEL Employment Pension Fund
in 1999 were given entirely or partly
on the basis of alcohol-induced dis-
eases.  Alcohol-induced diseases are,
indeed, important grounds for dis-
ability pensions within the LEL sec-
tors.  But, the majority of the pen-
sions for which alcohol is responsi-
ble in this particular Pension Fund
are so-called “paid-up free policy
pensions” which means that the em-
ployees have entered the temporary
employees’ sector very late and
probably on account of alcohol
problems.
The statistics show that alcohol-
associated mortality has increased
significantly in some sectors in par-
ticular, for instance among restau-
rant employees, fishermen and doc-
tors.  This mortality appears to be
linked with e.g. occupational motili-
ty as well as some other factors as-
sociated with work, such as expo-
sure to aliphatic and aromatic hy-
drocarbons and other solvents.
When examining the association be-
tween an occupation and alcohol
consumption consideration needs al-
so to be given to the type of employ-
ees becoming engaged in these occu-
pations, the availability of alcohol,
working cultures etc.
Occupational aspects should to
an increasing degree be considered
in the investigation of health haz-
ards caused by alcohol.  It is hard to
pin-point the causal relationships in
this issue; it requires wide-ranging
and varied research.
How to treat the problem of alco-
hol at the level of the society?
From the national health point of
view, heavy consumption of alcohol
is a considerable health risk which
according to available forecasts will
continue to expand.  Reduced tax
on alcohol as required by the EU,
for example, will have an effect in
this direction. The opportunities for
dissemination of health information
have been exceptionally good in Fin-
land.  Our occupational health ser-
vices and health centre system are
among the most wide-ranging in the
world.  Training in the issues of al-
cohol-related diseases has been or-
ganised at the universities for a long
time.  It has been possible to obtain
special competence in addiction
medicine since 1994 and the addic-
tion service network in the country
is relatively far-reaching.  Our
knowledge about alcohol-related
health hazards has increased expo-
nentially and Finland is a world
leader in the research into alcohol-
related issues.
Why, then, are the harmful ef-
fects caused by alcohol continually
growing?  The ineffectiveness of the
measures available is reflected in, for
instance, the increasing consumption
of alcohol among doctors them-
selves which in a way will set an ex-
ample for the community.  Collec-
tive control has proven effective pre-
viously: the number of deaths from
cirrhosis of the liver was consider-
ably reduced during the prohibition
act.  Would education of the type
provided by the example of ‘Turmi-
olan Tommi’ [a figure used in the
past as a national deterrent and a
warning]  be better than the present
liberal attitude?  The ball is in the
court of the politicians.
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There are at least three isoforms of
nitric oxide-synthesising enzymes
(nitric oxide synthase, NOS): endo-
thelial eNOS, nNOS in the nervous
system and inducible iNOS (in-
creased expression in inflammation
and other pathological processes). In
the circulatory system eNOS main-
tains vasodilation and inhibits plate-
let activation and cell adhesion to
the vascular wall. In animal models
it has been found to inhibit the de-
velopment of atherosclerosis, and
its deficiency may predispose to dia-
betes. In the peripheral nervous sys-
tem nitric oxide is involved in noci-
ception and acts as a NANC (non-
adrenergic non-cholinergic) trans-
mitter. In the brain NO affects e.g.
the vascular autoregulation; but ex-
cess amounts of nitric oxide may al-
so cause neurodegeneration.
Nitric oxide in common diseases 
Nitric oxide -mediated vasodilation
is reduced in, for example, hyperten-
sion, diabetes, hypercholesterol-
aemia, renal insufficiency and in
people who smoke. Vasodilation is
also reduced by even a mild systemic
inflammation; a distinct reduction in
vascular relaxation has been detect-
ed following vaccination.
High concentration of the endo-
genous NOS-inhibitor, asymmetrical
dimethylarginine (ADMA), is associ-
ated with renal insufficiency, hyper-
cholesterolaemia, insulin resistance
and, as a study of males in eastern
Finland revealed, acute coronary
events (1-5). The ADMA concentra-
tion in spinal cord fluid is reduced
with age, and has been found to be
considerably lower in Alzheimer pa-
tients than in control subjects of the
same age, which is an indication of
a link between the increased produc-
tion of NO and neurodegeneration
(6).
Nitric oxide in the skin
The skin produces nitric oxide both
via NOS and non-enzymatically (the
nitrate  in sweat is reduced to nitrite
which in the acidic environment of
the skin surface leads to NO pro-
duction). It takes part in cell differ-
entiation and development, healing
of wounds and the maintenance of
homeostasis and skin barrier func-
tion, particularly inhibiting microbes
(NO-sensitive in vitro are e.g. Her-
pes simplex, Propionibacterium ac-
nes and staphylococci, including
MRSA). Treatment of tinea pedis
and the mollusca with a nitric ox-
ide-releasing ointment has been suc-
cessful in small controlled studies (7,
8).
NOS is present in excess in in-
flammatory skin diseases and the
anti-inflammatory effect of cortico-
steroids may be mediated partly
through inhibition of nitric oxide.
Nitric oxide takes part in melano-
genesis, and together with PGE2 it is
an active mediator of sunburn ery-
thema; its effects are both cytopro-
tective and cytotoxic. The over-ex-
pression of NOS appears to be relat-
ed to the development of keloids
and to correlate with the degree of
malignancy of dermal tumours (9).
Inhaled nitric oxide
Inhaled nitric oxide has been in clin-
ical use for about ten years. It has
been used to improve gaseous ex-
change and to reduce the pulmonary
vascular constriction. The biggest
benefit is shown in the treatment of
neonatal respiratory disorders and
pulmonary hypertonia, where 15–20
ppm NO inhalation has reduced the
need for respiratory equipment, but
not the mortality (10). The treat-
ment is not harmless: high NO con-
centrations may cause methaemoglo-
binaemia, and rapid withdrawal of
NO inhalation may cause hypox-
aemia and exacerbation of pulmon-
ary hypertension. Studies on the
long-term effects of inhaled nitric
oxide are under way.
Nitric oxide is also used on other
pulmonary indications, though there
is no proof of benefit. Pulmonary
oedema associated with mountain
sickness may be a possible therapeu-
tic indication.  People living high in
the mountains develop more nitric
NO - what’s it all about?
The effects of nitric oxide (NO), the gaseous transmitter, on e.g. the efficacy and adverse effects
of anti-inflammatory analgesics, skin diseases and pulmonary function, were discussed at the
conference Nitric oxide-based drug therapy in April (William Harvey Research Conferences
2002).  The following samples of the papers presented at the conference are a reflection of pre-
sent-day views and research objectives.
Pirkko Paakkari
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oxide in their lungs than those living
on lower ground, which may be one
of the factors protective against pul-
monary oedema.
Anti-inflammatory analgesics of
the future – more nitric oxide?
Nitric oxide-releasing anti-inflam-
matory analgesics (NO-NSAID)
have in animal studies  been shown
to reduce gastrointestinal toxicity of
conventional NSAIDs. The protec-
tive effect is thought to be caused by
preservation the mucosal blood cir-
culation and inhibition of leucocyte
adherence to the vascular endotheli-
um. Healing of ulcers and other le-
sions is also improved with the NO
supplement, and this may be due to
increased angiogenesis and possibly
also the antibacterial effect of nitric
oxide (11,12).
In addition to its toxicity reduc-
ing effect, the NO-releasing agent
may also increase both the analgesic
and the anti-inflammatory effect of
anti-inflammatory analgesics. An ex-
cessive dose of nitric acid may, how-
ever, increase the toxicity targeted at
the gastrointestinal tract, and not all
NO-NSAID compounds have been
found to be equally good.
Or, less nitric oxide?
The over-expression of iNOS  in in-
flammation is manifested in in-
flamed joints, irritable colon and
asthma. Selective iNOS-inhibitors
have been developed which, in addi-
tion to these inflammatory diseases,
have been thought to offer opportu-
nities also to treat arthritis, stroke,
migraine, sepsis, multiple sclerosis,
transplant rejection reaction and
neuropathic pain and to include pre-
vention of the development of tu-
mours. The results of studies  on the
benefits of iNOS-inhibitors are con-
tradictory, since the inhibition of ni-
tric oxide synthesis has proved
harmful in some inflammation mod-
els. Treatment of sepsis has also pro-
duced varying responses: in a phase
III trial, a low dose of an iNOS-in-
hibitor  improved the prognosis  but
a high dose made it worse. Problems
are caused by the ambivalent nature
of the effects of nitric oxide even in
other ways – possible adverse effects
associated with iNOS-inhibition and
reduction in nitric oxide include, for
instance, immunosuppression, ath-
erosclerosis and impaired healing of
wounds.
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